Background Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease, and
there is increasing evidence that the interleukin (IL)‐36 pathway may play a role in the …

Background Clinical trial data for dupilumab, a monoclonal antibody against the interleukin‐
4 receptor (IL‐4Rα), have shown that it is safe and effective for the treatment of moderate to …

Abstract Background In JADE COMPARE, abrocitinib improved severity of atopic dermatitis
(AD) and demonstrated rapid itch relief. Objectives We examined clinically meaningful …

Atopic Dermatitis (AD) is an extremely pruritic inflammatory skin disease that has a
worldwide prevalence of approximately 2.69%, with significant variability by country. 1 In the …

Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …

Background Several clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-
13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis …

Recent epidemiological studies found the US prevalence of atopic dermatitis in adults to be
approximately 7%. In particular, one in four adults with atopic dermatitis report adult onset of …

Background The distribution of atopic dermatitis (AD) lesions and its impact on quality of life
(QOL) is not well established in the US adult population. Objective To elucidate the …

Atopic dermatitis (AD) is a common skin disease in childhood whose diagnosis requires
expertise in dermatology. Recent studies have indicated that host genes–microbial …

Background There is limited knowledge regarding prevalence and characteristics of atopic
dermatitis (AD) among young adults in the general population. Objectives To study AD …